Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA.
Division of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
Urol Oncol. 2019 Nov;37(11):814.e1-814.e7. doi: 10.1016/j.urolonc.2019.07.001. Epub 2019 Aug 14.
MicroRNAs (miRNAs/miRs) as circulating biomarkers for prostate cancer have yet to be determined. We examined whether circulating miRNAs in plasma could be employed as biomarkers of disease among men treated for prostate cancer by radical prostatectomy (RP).
The expression of 17 preselected circulating miRNAs associated with prostate cancer (miR-381, -34a, -365, -122, -375, -1255b, -34b, -450b-5p, -885-5p, -1260, -150, -378, -671-3p, -148a, and -224) or high-grade prostate cancer (miR-28 and -100) in plasma at prostate biopsy was examined in pre- and post-RP plasma of prostate cancer patients using real-time PCR and compared using Wilcoxon signed-ranked test. Wilcoxon rank sum test was used to compare the expression of miRNAs in pre-RP plasma between pathologic tumor stage (T2 vs. T3) and Gleason score (6-7 [3 + 4] vs. ≥ 7 [4 + 3]) groups. Partial correlation coefficient between the expression of miRNAs in pre-RP plasma and serum prostate-specific antigen (PSA) level at RP, adjusting for age, was calculated.
Twenty-nine men, aged 43 to 77 years, were included. Median follow-up time after RP was 55 days. There was no significant change in the expression of miRNAs in plasma from before to after RP. However, higher expression of miR-34a, -378, and 450b-5p in pre-RP plasma was observed among T3 compared to T2 patients (P values = 0.01). Overall, there were no statistically significant relationships observed between the expression of these circulating miRNAs and Gleason score and serum PSA at RP.
There was no significant change in the expression of circulating miRNAs in plasma from before to approximately 2 months after RP. This finding may be due to the lack of immediate effect RP may have on the expression of circulating miRNAs. However, higher expression of miR-34a, -378, and -450b-5p in plasma was found among patients with more advanced disease at RP. A longer follow-up time after RP is warranted to investigate RP's possible influence on circulating miRNAs among men treated for prostate cancer and to evaluate miRNAs' diagnostic potential for prostate cancer.
微小 RNA（miRNAs/miRs）作为前列腺癌的循环生物标志物尚未确定。我们研究了接受根治性前列腺切除术（RP）治疗的前列腺癌患者血浆中循环 miRNA 是否可用作疾病的生物标志物。
使用实时 PCR 检测了前列腺活检时血浆中与前列腺癌相关的 17 种选定的循环 miRNA（miR-381、-34a、-365、-122、-375、-1255b、-34b、-450b-5p、-885-5p、-1260、-150、-378、-671-3p、-148a 和 -224）或高级别前列腺癌（miR-28 和 -100）在前列腺癌患者 RP 前后血浆中的表达，并使用 Wilcoxon 符号秩检验进行比较。Wilcoxon 秩和检验用于比较病理肿瘤分期（T2 与 T3）和 Gleason 评分（6-7[3+4]与≥7[4+3]）组中 RP 前血浆中 miRNA 的表达。计算了 RP 前血浆中 miRNA 表达与血清前列腺特异性抗原（PSA）水平之间的偏相关系数，调整了年龄因素。
共纳入 29 名年龄 43 至 77 岁的男性。RP 后中位随访时间为 55 天。RP 前后血浆中 miRNA 的表达无显著变化。然而，T3 患者的 RP 前血浆中 miR-34a、-378 和 450b-5p 的表达较高（P 值分别为 0.01）。总体而言，这些循环 miRNA 的表达与 RP 时的 Gleason 评分和血清 PSA 之间没有统计学上的显著关系。
RP 前后约 2 个月血浆中循环 miRNA 的表达无明显变化。这一发现可能是由于 RP 对循环 miRNA 表达的即时影响不大。然而，在 RP 时疾病进展程度较高的患者的血浆中发现 miR-34a、-378 和 -450b-5p 的表达较高。需要更长的 RP 后随访时间来研究 RP 对接受前列腺癌治疗的男性循环 miRNA 的可能影响，并评估 miRNA 对前列腺癌的诊断潜力。
